{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:06:48Z","timestamp":1789016808995,"version":"build-2803163510"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T00:00:00Z","timestamp":1638835200000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Musculoskelet Disord"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Despite recent improvements in survival due to advances in treatment, the quality of life of patients with lymphoma may be compromised by the long-term complications of chemotherapy and steroid therapy. Among these, a potentially relevant problem is bone loss and the development of fragility fractures.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To provide further evidence of clinical or subclinical skeletal complications in correlation with biological variables and markers of bone disease in patients with complete response to therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>A cross-sectional observational study was conducted on subjects diagnosed with lymphoma with subsequent antineoplastic treatment, disease status after therapy defined as complete response disease for at least a year now. We performed: blood chemistry tests, imaging techniques and screening tools for the assessment of functional status and quality of life (SARC-F and mini-Osteoporosis Quality of Life).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Approximately 50% of patients had osteoporosis, with a prevalence of vertebral fractures of 65.5%. In most patients, we found hypovitaminosis D and high levels of parathyroid hormone (PTH). Furthermore, a statistically significant association was observed between high PTH levels and previous lymphoma treatment. Finally, the Mini-Osteoporosis Quality of life (mini-OQLQ) questionnaire demonstrated a loss of quality of life as a consequence of the change in bone status.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Patient treatment design for personalized chemotherapy would be desirable to reduce late effects on bone. Also, early prevention programs need to be applied before starting treatment. The most benefited subpopulations could be not only elderly but also young patients.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12891-021-04904-3","type":"journal-article","created":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T15:03:00Z","timestamp":1638889380000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Bone damage after chemotherapy for lymphoma: a real-world experience"],"prefix":"10.1186","volume":"22","author":[{"given":"S.","family":"Mancuso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalila","family":"Scaturro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Di Gaetano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Vitagliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Falco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Siragusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Gonnelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Letizia","family":"Mauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,7]]},"reference":[{"key":"4904_CR1","unstructured":"DamlajM, El FakihR, Hashmi SK. Evoluzione della sopravvivenza nel linfoma, mieloma e leucemia: metamorfosi del campo in cure di follow-up a lungo termine. Sangue Rev. 2019 Gen;33:63\u201373. 10.1016\/j.blre.2018.07.003."},{"key":"4904_CR2","doi-asserted-by":"crossref","unstructured":"Bedatsova l, Drake MT. L\u2019impatto scheletrico delle terapie contro il cancro. Br J Clin Pharmacol. 2019;85(6):1161\u20131168. 10.1111\/bcp.13866.(disponibile il 2020\u201306-).","DOI":"10.1111\/bcp.13866"},{"key":"4904_CR3","doi-asserted-by":"crossref","unstructured":"Westin JR,Thompson MA,Cataldo VD, Toth BB, Sanjorjo Pi, borghese S, Jimenez C, Murphy WA, Fanale M, Fayad L, Fowler N, Kwak L, McLaughlin Pi, Neelapu S, Pro B, Rodriguez A, Shah J, HagemeisterFB. Perdita ossea nei pazienti con linfoma prima di ricevere la terapia di prima linea.Clin Linfoma Mieloma Leuk. 2010 giugno;10,3:E32. Estratto 7.","DOI":"10.3816\/CLML.2010.n.042"},{"key":"4904_CR4","doi-asserted-by":"crossref","unstructured":"Thompson MA, Huen A, Toth BB, Vassilopoulou-Sellin R, Hoff AO, Murphy WA, Sanjoro H, Bekele BN, Arbuckle RB, Hagemeister FB.Osteopenia e osteoporosi nei pazienti con linfoma non Hodgkin non trattati: un problema di sopravvivenza importante e potenzialmente trattabile nel linfoma. JCO 2007 25:18_suppl, 9055\u20139055.","DOI":"10.1200\/jco.2007.25.18_suppl.9055"},{"issue":"9","key":"4904_CR5","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.1007\/s00520-018-4143-z","volume":"26","author":"R Ruchlemer","year":"2018","unstructured":"Ruchlemer R, Amit-Kohn M, Tvito A, Sindelovsky I, Zimran A, Raveh-Brawer D. Perdita ossea e neoplasie ematologiche negli adulti: uno studio pilota. Sostieni la cura del cancro. 2018;26(9):3013\u201320. https:\/\/doi.org\/10.1007\/s00520-018-4143-z.","journal-title":"Sostieni la cura del cancro."},{"key":"4904_CR6","doi-asserted-by":"crossref","unstructured":"Westin JR, Thompson MA, Cataldo VD,Fayad LE, Fowler N, Fanale MA,Neelapu S,Samaniego F,Romaguera J, Shah J,McLaughlin P, Pro B,Kwak LW,Sanjorjo P,Murphy WA,Jimenez C, Toth BB, Dong W, HagemeisterFB. Acido zoledronico per la prevenzione della perdita ossea nei pazienti sottoposti a terapia primaria per i linfomi: uno studio prospettico, randomizzato e controllato di fase III.Clin Linfoma Mieloma Leuk. aprile 2013; 13(2): 10.1016\/j.clml.2012.11.002.","DOI":"10.1016\/j.clml.2012.11.002"},{"key":"4904_CR7","doi-asserted-by":"crossref","unstructured":"Paccou J,Merlusca l, Henry-Desailly io,Concessionario UN,Gruson B,Royer B,Charbonnier UN,Ursu D,Desailloud R,Garidi R,Kamel S,Sevestre H,marolleau JP,Fardellone P,Damaj g. Alterazioni della densit\u00e0 minerale ossea e dei marker di turnover osseo negli adulti di nuova diagnosi con linfoma sottoposti a chemioterapia: un progetto pilota prospettico di 1 anno studia. Anna Oncol. 25 febbraio 2014(2):481\u20136. 10.1093\/annonc\/mdt560.","DOI":"10.1093\/annonc\/mdt560"},{"key":"4904_CR8","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1186\/1471-2407-10-337","volume":"10","author":"LA Smith","year":"2010","unstructured":"Smith LA, Cornelius VR, Plummer CJ, Levitt G, Verrill M, Canney P, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer. 2010;10:337. https:\/\/doi.org\/10.1186\/1471-2407-10-337.","journal-title":"BMC Cancer."},{"issue":"6","key":"4904_CR9","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1080\/10428194.2020.1723015","volume":"61","author":"J Baech","year":"2020","unstructured":"Baech J, Hansen SM, Jakobsen LH, \u00d8vlisen AK, Severinsen MT, Brown PN, et al. Increased risk of osteoporosis following commonly used first-line treatments for lymphoma: a Danish Nationwide Cohort Study. Leuk Lymphoma. 2020;61(6):1345\u201354. https:\/\/doi.org\/10.1080\/10428194.2020.1723015.","journal-title":"Leuk Lymphoma."},{"key":"4904_CR10","doi-asserted-by":"crossref","unstructured":"Anargyrou K, Fotiou D, Vassilakopoulos TP, Christoulas D, Makras P, Dimou M, Ntanasis-Stathopoulos I, Masouridou S, Angelopoulou MK, Papatheodorou A, Tsionos K, Panayiotidis P, Dimopoulos MA, Terpos E. Bassa densit\u00e0 minerale ossea e alto turnover osseo in pazienti con linfoma non Hodgkin (NHL) che ricevono terapia di prima linea: risultati di uno studio prospettico multicentrico. Emassfera. 24 settembre 2019;3(6):e303. 10.1097\/HS9.00000000000000303. eCollection 2019 dic.","DOI":"10.1097\/HS9.0000000000000303"},{"issue":"2","key":"4904_CR11","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s00198-020-05577-9","volume":"32","author":"J Bodden","year":"2021","unstructured":"Bodden J, Sun D, Joseph GB, Huang LW, Andreadis C, Hughes-Fulford M, et al. Identification of non-Hodgkinlymphomapatientsatrisk for treatment-relatedvertebraldensityloss and fractures. OsteoporosInt. 2021;32(2):281\u201391. https:\/\/doi.org\/10.1007\/s00198-020-05577-9.","journal-title":"OsteoporosInt."},{"issue":"2","key":"4904_CR12","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/cphy.c140071","volume":"6","author":"SJ Khundmiri","year":"2016","unstructured":"Khundmiri SJ, Murray RD, Lederer E. PTH and Vitamin D. Compr Physiol. 2016;6(2):561\u2013601. https:\/\/doi.org\/10.1002\/cphy.c140071.","journal-title":"Compr Physiol."},{"issue":"3","key":"4904_CR13","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/ejh.12818","volume":"98","author":"PM Kulling","year":"2017","unstructured":"Kulling PM, Olson KC, Olson TL, Feith DJ, Loughran TP Jr. Vitamin D in hematological disorders and malignancies. Eur J Haematol. 2017;98(3):187\u201397. https:\/\/doi.org\/10.1111\/ejh.12818.","journal-title":"Eur J Haematol."},{"issue":"7","key":"4904_CR14","doi-asserted-by":"publisher","first-page":"300060520943421","DOI":"10.1177\/0300060520943421","volume":"48","author":"V Graklanov","year":"2020","unstructured":"Graklanov V, Popov V. Vitamin D levels in patients with non-Hodgkin lymphoma\/diffuse large B-cell lymphoma, chronic lymphocytic leukemia and multiple myeloma. J Int Med Res. 2020;48(7):300060520943421. https:\/\/doi.org\/10.1177\/0300060520943421.","journal-title":"J Int Med Res."},{"key":"4904_CR15","doi-asserted-by":"crossref","unstructured":"Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM; Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011 Jul;96(7):1911\u201330. 10.1210\/jc.2011-0385. Epub 2011 Jun 6. Erratum in: J Clin Endocrinol Metab. 2011 Dec;96(12):3908.","DOI":"10.1210\/jc.2011-0385"},{"issue":"Suppl 1","key":"4904_CR16","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12893-018-0459-3","volume":"18","author":"F Medas","year":"2019","unstructured":"Medas F, Erdas E, Loi G, Podda F, Barca L, Pisano G, et al. Intraoperative parathyroid hormone (PTH) testing in patients with primary hyperparathyroidism and PTH levels in the normal range. BMC Surg. 2019;18(Suppl 1):124. https:\/\/doi.org\/10.1186\/s12893-018-0459-3.","journal-title":"BMC Surg."},{"key":"4904_CR17","doi-asserted-by":"crossref","unstructured":"Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. OsteoporosInt 1994;4:36881.","DOI":"10.1007\/BF01622200"},{"key":"4904_CR18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jot.2018.08.004","volume":"15","author":"YXJ W\u00e1ng","year":"2018","unstructured":"W\u00e1ng YXJ, Deng M, He LC, Che-Nordin N, Santiago FR. Osteoporotic vertebral endplate and cortex fractures: A pictorial review. J Orthop Translat. 2018;15:35\u201349. https:\/\/doi.org\/10.1016\/j.jot.2018.08.004.","journal-title":"J Orthop Translat."},{"key":"4904_CR19","doi-asserted-by":"crossref","unstructured":"Malmstrom TK, Miller DK, Simonsick EM, Ferrucci L, Morley JE. SARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes. J Cachexia Sarcopenia Muscle. 2016;7(1):28\u201336. doi: 10.1002\/jcsm.12048.","DOI":"10.1002\/jcsm.12048"},{"key":"4904_CR20","doi-asserted-by":"crossref","unstructured":"Ida S, Kaneko R, Murata K. SARC-F for Screening of Sarcopenia Among Older Adults: A Meta-analysis of Screening Test Accuracy. J Am Med Dir Assoc. 2018;19(8):685\u2013689. 10.1016\/j.jamda.2018.04.001.","DOI":"10.1016\/j.jamda.2018.04.001"},{"key":"4904_CR21","doi-asserted-by":"crossref","unstructured":"Ioannidis G, Gordon M, Adachi JD. Quality of life in osteoporosis. NursClin North Am. 2001;36(3):481\u20139, ix.","DOI":"10.1016\/S0029-6465(22)02570-1"},{"key":"4904_CR22","doi-asserted-by":"publisher","unstructured":"Hochberg J, Flower A, Brugieres L, S.Cairo M. NHL in adolescents and young adults: A unique population. 09 May 2018. Pediatric Blood & Cancer. https:\/\/doi.org\/10.1002\/pbc.27073. Review.","DOI":"10.1002\/pbc.27073"},{"key":"4904_CR23","doi-asserted-by":"crossref","unstructured":"Lips P, van Schoor NM. The effect of vitamin D on bone and osteoporosis. BestPract Res ClinEndocrinolMetab. 2011 Aug;25(4):585\u201391. 10.1016\/j.beem.2011.05.002.","DOI":"10.1016\/j.beem.2011.05.002"},{"key":"4904_CR24","doi-asserted-by":"publisher","unstructured":"Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266\u2013281. doi: https:\/\/doi.org\/10.1056\/NEJMra070553.","DOI":"10.1056\/NEJMra070553"},{"issue":"7","key":"4904_CR25","doi-asserted-by":"publisher","first-page":"300060520943421","DOI":"10.1177\/0300060520943421","volume":"48","author":"V Graklanov","year":"2020","unstructured":"Graklanov V, Popov V. Vitamin D levels in patients with non-Hodgkinlymphoma\/diffuse large B-celllymphoma, chroniclymphocyticleukemia and multiple myeloma. J IntMed Res. 2020;48(7):300060520943421. https:\/\/doi.org\/10.1177\/0300060520943421.","journal-title":"J IntMed Res."},{"key":"4904_CR26","doi-asserted-by":"publisher","unstructured":"Hohaus S, Tisi MC, Bellesi S, Maiolo E, Alma E, Tartaglia G, Corrente F, Cuccaro A, D\u2032Alo\u2019 F, Basile U, Larocca LM, De Stefano V. Vitamin D deficiency and supplementation in patients with aggressive B-celllymphomastreated with immunochemotherapy. CancerMed. 2018n;7(1):270\u2013281. doi: https:\/\/doi.org\/10.1002\/cam4.1166.","DOI":"10.1002\/cam4.1166"},{"key":"4904_CR27","doi-asserted-by":"crossref","unstructured":"Reginster JY, Beaudart C, Buckinx F, Bruy\u00e8reO. Osteoporosis and sarcopenia: two diseases or one? Curr Opin Clin Nutr Metab Care. 2016;19(1):31\u20136. 10.1097\/MCO.0000000000000230.","DOI":"10.1097\/MCO.0000000000000230"},{"key":"4904_CR28","doi-asserted-by":"crossref","unstructured":"Greco EA, Pietschmann P, Migliaccio S. Osteoporosis and Sarcopenia Increase Frailty Syndrome in the Elderly. Front Endocrinol (Lausanne). 2019;10:255. 10.3389\/fendo.2019.00255. eCollection 2019.Free PMC article. Review.","DOI":"10.3389\/fendo.2019.00255"},{"key":"4904_CR29","doi-asserted-by":"crossref","unstructured":"Hunter GR, Singh H, Carter SJ, Bryan DR, Fisher G. Sarcopenia and Its Implications for Metabolic Health. J Obes. 2019;2019:8031705. 10.1155\/2019\/8031705. eCollection 2019.","DOI":"10.1155\/2019\/8031705"},{"issue":"9","key":"4904_CR30","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1093\/annonc\/mdx271","volume":"28","author":"F Bozzetti","year":"2017","unstructured":"Bozzetti F. Forcing the vicious circle: sarcopenia increases toxicity, decreases response tochemotherapy and worsens with chemotherapy. Ann Oncol. 2017;28(9):2107\u201318. https:\/\/doi.org\/10.1093\/annonc\/mdx271.","journal-title":"Ann Oncol."},{"key":"4904_CR31","doi-asserted-by":"crossref","unstructured":"Davis MP, Panikkar R. Sarcopeniaassociated with chemotherapy and targeted agents for cancertherapy. AnnPalliatMed. 2019 Jan;8(1):86\u2013101. 10.21037\/apm.2018.08.02.","DOI":"10.21037\/apm.2018.08.02"},{"issue":"5","key":"4904_CR32","doi-asserted-by":"publisher","first-page":"C744","DOI":"10.1152\/ajpcell.00002.2018","volume":"315","author":"BA Guigni","year":"2018","unstructured":"Guigni BA, Callahan DM, Tourville TW, Miller MS, Fiske B, Voigt T, et al. Skeletal muscle atrophy and dysfunction in breast cancer patients: role for chemotherapy-derived oxidant stress. Am J Physiol Cell Physiol. 2018;315(5):C744\u201356. https:\/\/doi.org\/10.1152\/ajpcell.00002.2018.","journal-title":"Am J Physiol Cell Physiol."},{"key":"4904_CR33","doi-asserted-by":"crossref","unstructured":"Monterosso L, Taylor K, Platt V, Lobb E, Krishnasamy M, Musiello T, Bulsara C, Stratton K, Joske D. A qualitative study of the post-treatment experiences and support needs of survivors of lymphoma. Eur J Oncol Nurs. 2017;28:62\u201368. 10.1016\/j.ejon.2017.03.002.","DOI":"10.1016\/j.ejon.2017.03.002"},{"key":"4904_CR34","doi-asserted-by":"crossref","unstructured":"Compaci G, Conte C, Oberic L, Ysebaert L, Laurent G, Despas F. Sustained degradation of quality of life in a subgroup of lymphoma survivors: a two-year prospective survey. BMC Cancer. 2019;19(1):1178. 10.1186\/s12885-019-6337-2.","DOI":"10.1186\/s12885-019-6337-2"},{"key":"4904_CR35","doi-asserted-by":"publisher","unstructured":"Frick MA, Vachani CC, Hampshire MK, Bach C, Arnold-Korzeniowski K, Metz JM, Hill-Kayser CE. Patient-Reported Survivorship Care Practices and Late Effects After Treatment of Hodgkin and Non-Hodgkin Lymphoma. JCO Clin Cancer Inform 2018;2:1\u201310. https:\/\/doi.org\/10.1200\/CCI.18.00015.","DOI":"10.1200\/CCI.18.00015"},{"key":"4904_CR36","doi-asserted-by":"publisher","first-page":"153473541882205","DOI":"10.1177\/1534735418822056","volume":"18","author":"MR Andersen","year":"2019","unstructured":"Andersen MR, Sweet E, Hager S, Gaul M, Dowd F, Standish LJ. Effects of Vitamin D Use on Health-Related Quality of Life of Breast Cancer Patients in Early Survivorship. Integr Cancer Ther. 2019;18:1534735418822056. https:\/\/doi.org\/10.1177\/1534735418822056.","journal-title":"Integr Cancer Ther."},{"issue":"8","key":"4904_CR37","doi-asserted-by":"publisher","first-page":"799","DOI":"10.3390\/nu9080799","volume":"9","author":"P Manoy","year":"2017","unstructured":"Manoy P, Yuktanandana P, Tanavalee A, Anomasiri W, Ngarmukos S, Tanpowpong T, et al. Vitamin D Supplementation Improves Quality of Life and Physical Performance in Osteoarthritis Patients. Nutrients. 2017;9(8):799. https:\/\/doi.org\/10.3390\/nu9080799.","journal-title":"Nutrients."},{"key":"4904_CR38","doi-asserted-by":"crossref","unstructured":"Murthy L, Dreyer P, Suriyaarachchi P, Gomez F, Curcio CL, Boersma D, Duque G. Association between high levels of parathyroid hormone and frailty: the Nepean Osteoporosis and Frailty (NOF) study.J Frailty Aging. 2018;7(4):253\u2013257. doi: 10.14283\/10.14283\/jfa.2018.22..","DOI":"10.14283\/jfa.2018.22"},{"key":"4904_CR39","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.maturitas.2018.04.006","volume":"113","author":"P Suriyaarachchi","year":"2018","unstructured":"Suriyaarachchi P, Gomez F, Curcio CL, Boersma D, Murthy L, Grill V, et al. High parathyroid hormone levels are associated with osteosarcopenia in older individuals with a history of falling. Maturitas. 2018;113:21\u20135. https:\/\/doi.org\/10.1016\/j.maturitas.2018.04.006.","journal-title":"Maturitas."},{"key":"4904_CR40","doi-asserted-by":"publisher","first-page":"7257913","DOI":"10.1155\/2020\/7257913","volume":"2020 Apr 9","author":"Y Jiang","year":"2020","unstructured":"Jiang Y, Liao L, Li J, Wang L, Xie Z. Older Age Is Associated with Decreased Levels of VDR, CYP27B1, and CYP24A1 and Increased Levels of PTH in Human Parathyroid Glands. Int J Endocrinol. 2020;2020 Apr 9:7257913. https:\/\/doi.org\/10.1155\/2020\/7257913.","journal-title":"Int J Endocrinol."},{"issue":"9880","key":"4904_CR41","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(13)60313-X","volume":"381","author":"D Cunningham","year":"2013","unstructured":"Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P, et al. Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone in Patients With Newly Diagnosed Diffuse Large B-cell non-Hodgkin Lymphoma: A Phase 3 Comparison of Dose Intensification With 14-day Versus 21-day\u00a0Cycles. Lancet. 2013;381(9880):1817\u201326. https:\/\/doi.org\/10.1016\/S0140-6736(13)60313-X.","journal-title":"Lancet"},{"issue":"6","key":"4904_CR42","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1046\/j.0306-5251.2001.1385.x","volume":"51","author":"TP vanStaa","year":"2001","unstructured":"vanStaa TP, Abenhaim L, Cooper C, Zhang B, LeufkensHGM. Public health impact of adverse bone effects of oral corticosteroids. Br J ClinPharmacol. 2001;51(6):601\u20137. https:\/\/doi.org\/10.1046\/j.0306-5251.2001.1385.x.","journal-title":"Br J ClinPharmacol."},{"key":"4904_CR43","doi-asserted-by":"crossref","unstructured":"Sato AY, Peacock M, Bellido T. Gluocorticoid excess in bone and muscle. Clin Rev Bone Miner Metab. Author manuscript; available in PMC 2019 Mar 1.Published in final edited form as: Clin Rev Bone Miner Metab. 2018; 16(1): 33\u201347. Published online 2018 Feb 5. 10.1007\/s12018-018-9242-3.","DOI":"10.1007\/s12018-018-9242-3"},{"key":"4904_CR44","doi-asserted-by":"crossref","unstructured":"Gianni L, Herman EH, Lipshultz SE, Minotti G, Sarvazyan N, Sawyer DB. Anthracyclinecardiotoxicity: from bench to bedside. J Clin Oncol. 2008;26(22):3777\u201384. 10.1200\/JCO.2007.14.9401.","DOI":"10.1200\/JCO.2007.14.9401"},{"key":"4904_CR45","doi-asserted-by":"crossref","unstructured":"Boyne DJ, Mickle AT, Brenner DR, Friedenreich CM, Cheung WY, Tang KL, Wilson TA, Lorenzetti DL, James MT, Ronksley PE, Rabi DM. Long-term risk of cardiovascular mortality in lymphoma survivors: A systematic review and meta-analysis. Cancer Med. 2018; 7(9): 4801\u20134813. Published online 2018 Aug 15. 10.1002\/cam4.1572.","DOI":"10.1002\/cam4.1572"},{"key":"4904_CR46","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1200\/JCO.2002.09.038","volume":"20","author":"GM Dores","year":"2002","unstructured":"Dores GM, Metayer C, Curtis RE, et al. Second malignant neoplasms among long-term survivors of Hodgkin\u2019s disease: A population-based evaluation over 25\u00a0years. J ClinOncol. 2002;20:3484\u201394.","journal-title":"J ClinOncol"},{"key":"4904_CR47","doi-asserted-by":"publisher","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA. Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification. J ClinOncol. 2014; 32(27): 3059\u20133067. Published online 2014 Aug 11. https:\/\/doi.org\/10.1200\/JCO.2013.54.8800.","DOI":"10.1200\/JCO.2013.54.8800"}],"container-title":["BMC Musculoskeletal Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-021-04904-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12891-021-04904-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-021-04904-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T15:02:41Z","timestamp":1673967761000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmusculoskeletdisord.biomedcentral.com\/articles\/10.1186\/s12891-021-04904-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["4904"],"URL":"https:\/\/doi.org\/10.1186\/s12891-021-04904-3","relation":{},"ISSN":["1471-2474"],"issn-type":[{"value":"1471-2474","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"3 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"Data were obtained and analysed according to the Helsinki declaration. Approval was granted by the Ethics Committee of the University Hospital of Palermo, Italy (n\u00b0 2\/2018).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethic approval"}},{"value":"Written informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"1024"}}